Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | PTPRF | P10586 | 1/20 | 0.52 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.52 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.45 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23802828 | 1.00 | LMNA (0.58) | LMNAPTPRFPTPN2PTPN1PTPN11 | |
| SCHEMBL12454298 | 0.85 | MEN1 (0.53) | LMNAPTPRFPTPN2PTPN1PTPN11 | |
| SCHEMBL1823141 | 0.83 | SIGMAR1 (0.55) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL23023068 | 0.83 | SIGMAR1 (0.55) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL7041284 | 0.83 | SIGMAR1 (0.55) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL5003894 | 0.82 | MEN1 (0.56) | LMNAPTPRFPTPN2PTPN1PTPN11 | |
| SCHEMBL11410509 | 0.81 | LMNA (0.51) | LMNAPTPRFPTPN2PTPN1PTPN11 | |
| SCHEMBL10244258 | 0.81 | LMNA (0.62) | LMNAMEN1KMT2ASMN1; SMN2NPC1 | |
| SCHEMBL10245251 | 0.81 | LMNA (0.62) | LMNAMEN1KMT2ASMN1; SMN2NPC1 | |
| SCHEMBL2797012 | 0.80 | SIGMAR1 (0.68) | LMNAPTPRFPTPN2PTPN1PTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3515896-B1 | CHIRAL CYCLEN COMPOUNDS AND THEIR USES | UNIV HONG KONG POLYTECHNIC (CN) | 2024-08-21 | — | — | EP | disclosed |
| US-11357873-B2 | Chiral cyclen compounds and their uses | THE HONG KONG POLYTECHNIC UNIVERSITY (CN) | 2022-06-14 | — | — | US | disclosed |
| US-20210283278-A1 | CHIRAL CYCLEN COMPOUNDS AND THEIR USES | THE HONG KONG POLYTECHNIC UNIVERSITY (CN) | 2021-09-16 | — | — | US | disclosed |
| US-6826033-B2 | BETA 3 ADRENERGIC RECEPTOR AGONISTS; TREATMENT OF POLLAKIURIA, URINARY INCONTINENCE, OBESITY OR DIABETES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-11-30 | — | — | US | disclosed |
| US-20040037022-A1 | Aminoalcohol derivatives | ASTELLAS PHARMA INC. (JP) | 2004-02-26 | — | — | US | disclosed |
| WO-2002024635-A2 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11357873-B2 | Chiral cyclen compounds and their uses | DCTN3, DCTN1, CDK3 | LMNA 2197/4885PTPRF 4637/4885PTPN2 3811/4885 |
| US-20210283278-A1 | CHIRAL CYCLEN COMPOUNDS AND THEIR USES | DCTN3, DCTN1, CDK3 | LMNA 2197/4885PTPRF 4637/4885PTPN2 3811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.